Phase 3 N=40 Perioperative Iron for Colorectal Cancer (PICoC Study)
Cancer Colon
Primary: The Feasibility of Running the Study, to See if it Could be Run as a Large Multi-centre Study — 16; 18 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=2,713 COmmuNity-engaged SimULation Training for Blood Pressure Control
Hypertension
Primary: Blood Pressure — 137.6; 136.4; 82.1; 81.8 mm Hg
N/A N=255 Analysis of the Relationship Between Early Postoperative Anemia and the Evolution of Autonomy at 6 Months in Patients 75 Years of Age and Older Operated on Following a Fracture of the Upper End of the Femur
Femoral Fracture
Primary: Hemoglobin Rate — 10 g/dl
N/A N=222 Patient Self-sampling of HPV to Screen for Cervical Cancer
Human Papilloma Virus
Primary: Concordance of Patient-collected and Clinician-collected Samples to Detect HPV Infection — 98; 94; 99; 95 Total Percentage Agreement
Phase 3 N=2,530 Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
Dyslipidemias · High Cholesterol · Hypercholesterolemia
Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] — 2.70; -29.94 percent change from baseline — p=<.0001
Phase 3 N=108 Intranasal Vasopressin Treatment in Children With Autism
Autism · Autism Spectrum Disorder · ASD
Primary: Change From Baseline in Parent Rated Social Responsiveness Scale, Second Edition (SRS-2) Total Scores During Treatment. — 81.3690; 79.6795; 82.2281; -5.6779 T-score
Phase 2 N=27 LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
Melanoma
Primary: Overall Response — 0; 1; 1; 0 Participants
Phase 1 N=24 A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib — 22380; 51570; 21070…
N/A N=52 Behavioral Activation-Rehabilitation to Improve Depressive Symptoms & Physical Function After Acute Respiratory Failure
Respiratory Insufficiency · Depression · Rehabilitation
Primary: Feasibility Measure Per Participant — 0.8 proportion of intended visits
Phase 2 N=35 Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease
Huntington Disease
Primary: Efficacy by UHDRS-TMS — -1.23; 0.84; 8.91 score on a scale/year
Phase 1 N=20 A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib — 26160; 28400; 7973…
Phase 3 N=224 Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) Against T. Trichiura — 69.4; 16.2; 11.8 percentage of participants cured (%)
Phase 2 N=281 A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B
Hepatitis B, Chronic
Primary: Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at 24 Weeks Post-End of Treatment (EOT) — 0; 0; 6.7; 3.3 percentage of participants
N/A N=468 Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship
Sepsis
Primary: All-cause Mortality and Hospital Readmission Rate — 1023; 684 Participants
Phase 2 N=226 MVA Post-Event: Administration Timing and Boost Study
Smallpox
Primary: Geometric Mean Titer (GMT) of Bavarian Nordic's (BN) Plaque Reduction Neutralizing Antibody Titer (PRNT) Assay in Groups A and B — 10.8; 30.2 titer